RESEARCH, DEVELOPMENT, PRODUCTION, AND SAFETY OF BIOSYNTHETIC HUMAN INSULIN

被引：67

作者：

CHANCE, RE

FRANK, BH

机构：

[1] Department MC797, Lilly Corporate Center, Mail Drop 1543, Indianapolis

来源：

DIABETES CARE | 1993年 / 16卷

关键词：

D O I：

10.2337/diacare.16.3.133

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This paper provides some historical aspects on the research and development of Humulin(R) (rDNA origin), the first human health-care product derived from rDNA technology more than a decade ago. Also referred to as biosynthetic human insulin, Humulin(R) is currently produced via the human proinsulin route, using an Escherichia coli fermentation process. The authenticity, high purity, and safety of BHI has been investigated and verified by a complex battery of analytical and physicochemical methods. The daily treatment of more than two million diabetic patients worldwide with this rDNA human insulin not only demonstrates the value of rDNA technology in providing an important medical product, it is assurance that diabetic patients will have unlimited supplies of this vital hormone as well as potential analogue refinements.

引用

页码：133 / 142

页数：10

共 105 条

[1]

ATKINS LM, 1987, J ASSOC OFF ANA CHEM, V70, P610

[2]

BAKER RS, 1981, LANCET, V2, P1139

[3]

BECKMAN AO, 1988, DEC M NAT AC SCI BEC

[4]

BLACKSHEAR PJ, 1986, ASAIO, V9, P646

[5]

Bliss M, 1982, DISCOVERY INSULIN

[6]

BURNETT JP, 1983, EXPT MANIPULATION GE, P259

[7]

BURNETT JP, 1980, PHARM TECH, V4, P42

[8]

BYRNE G, 1988, SCIENCE, V241, P907, DOI 10.1126/science.241.4868.907-b

[9]

Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721

[10] CHEMICAL, PHYSICAL, AND BIOLOGIC PROPERTIES OF BIOSYNTHETIC HUMAN INSULIN [J].

CHANCE, RE ;

KROEFF, EP ;

HOFFMANN, JA ;

FRANK, BH .

DIABETES CARE, 1981, 4 (02) :147-154

← 1 2 3 4 5 6 7 8 9 10 →